
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


PureTech Health PLC (PRTC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: PRTC (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -9.14% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 453.70M USD | Price to earnings Ratio - | 1Y Target Price 53.25 |
Price to earnings Ratio - | 1Y Target Price 53.25 | ||
Volume (30-day avg) 2719 | Beta 0.95 | 52 Weeks Range 17.00 - 34.00 | Updated Date 02/18/2025 |
52 Weeks Range 17.00 - 34.00 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -23054.86% |
Management Effectiveness
Return on Assets (TTM) -13.39% | Return on Equity (TTM) -22.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -38900442 | Price to Sales(TTM) 969.45 |
Enterprise Value -38900442 | Price to Sales(TTM) 969.45 | ||
Enterprise Value to Revenue 348.82 | Enterprise Value to EBITDA -51.93 | Shares Outstanding 23942100 | Shares Floating 158597465 |
Shares Outstanding 23942100 | Shares Floating 158597465 | ||
Percent Insiders - | Percent Institutions 1.57 |
AI Summary
PureTech Health PLC: A Comprehensive Overview
Company Profile
History and Background:
PureTech Health PLC (PRTC) is a clinical-stage biotherapeutics company focused on discovering and developing novel treatments for inflammatory, fibrotic, and cardiovascular diseases. Founded in 2010, the company has its headquarters in Boston, Massachusetts, with a research & development site in Cambridge, UK. PureTech operates through two segments:
- Late-stage clinical assets: This includes a portfolio of four clinical-stage product candidates: LYT-100 (an oral therapy for inflammatory and fibrotic diseases), LYT-200 (an oral therapy for autoimmune and inflammatory diseases), AKB-492 (a gene therapy for high-risk cardiovascular disease), and LYT-300 (a gene therapy for alpha-1 antitrypsin deficiency).
- Early-stage discovery and development programs: This segment includes a pipeline of preclinical programs focused on inflammatory and fibrotic diseases, immunology, and synthetic biology.
Core Business Areas:
- Discovery and development of novel therapeutic drugs: PureTech focuses on developing oral therapies, gene therapies, and antibody-drug conjugates.
- Collaboration with academic and industry partners: They leverage partnerships to accelerate research and development efforts.
- Commercialization of approved drugs: Once a drug receives regulatory approval, PureTech partners with pharmaceutical companies for distribution and marketing.
Leadership Team and Corporate Structure:
- Daphne Zohar: CEO, with extensive experience in the pharmaceutical industry, including Roche and Genentech.
- Joseph Bolen, MD: Chief Medical Officer, previously held leadership roles at Pfizer and Amgen.
- David A. Simpson: Chief Financial Officer, brings over 25 years of experience in finance and accounting.
- Board of Directors: Comprised of industry veterans with expertise in drug development, finance, and venture capital.
Top Products and Market Share
- LYT-100: An oral therapy for inflammatory bowel disease (IBD) targeting LFA-1, an integrin involved in both chronic and acute inflammation. Phase 3 trials are ongoing.
- LYT-200: An oral therapy for moderate-to-severe psoriasis targeting IL-17A, a key cytokine in autoimmune diseases. Topline data from Phase 2a trial is expected in Q4 2023.
- AKB-492: A gene therapy for patients with documented coronary or peripheral artery disease. Phase 1b/2a trial is ongoing.
- LYT-300: A gene therapy for alpha-1 antitrypsin deficiency, a rare genetic disorder. Phase 1/2a trial is ongoing.
Market Share:
The company's current products are in development, hence they do not hold a market share in any specific therapeutic area. However, the market potential for LYT-100, LYT-200, AKB-492, and LYT-300 is significant.
- The global market for IBD therapies is estimated to reach $14.2 billion by 2027.
- The global market for psoriasis treatments is expected to reach $18.4 billion by 2027.
- The global cardiovascular gene therapy market is projected to reach $1.4 billion by 2028.
- The global market for alpha-1 antitrypsin deficiency treatments is estimated to reach $3.4 billion by 2027.
Competitive Landscape:
- IBD: Major competitors include Pfizer (IBD portfolio), AbbVie (Humira), and Johnson & Johnson (Stelara).
- Psoriasis: Major competitors include AbbVie (Skyrizi), Eli Lilly (Taltz), and Novartis (Cosentyx).
- Gene therapy for cardiovascular diseases: Competitors include BioMarin Pharmaceutical (valoctocogene roxaparvovec) and uniQure (etranacogene dezaparvovec).
- Alpha-1 antitrypsin deficiency: Major competitor is CSL Behring (Glassia).
Total Addressable Market (TAM)
PureTech Health's TAM is vast, encompassing the global markets for inflammatory diseases, fibrotic diseases, cardiovascular diseases, and alpha-1 antitrypsin deficiency. Combining the individual market sizes mentioned above, PureTech's potential TAM is estimated to be over $37 billion.
About PureTech Health PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-11-16 | CEO & Executive Director Dr. Bharatt M. Chowrira J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 90 | Website https://www.puretechhealth.com |
Full time employees 90 | Website https://www.puretechhealth.com |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.